Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Strychnos nux-vomica, specifically in the homeopathic preparation Nux vomica C200, is a highly diluted plant extract derived from the seeds of the Strychnos nux-vomica tree. It is being investigated by the Medical University of Vienna in a Phase 4 clinical trial for the prophylaxis of postoperative atrial fibrillation (POAF) in adult patients undergoing cardiac surgery, such as aortocoronary bypass or heart valve surgery with cardiopulmonary bypass. Administered sublingually as globules, the preparation is evaluated for its potential to prevent arrhythmias and its effects on electrolyte balance. As a homeopathic remedy, it lacks a conventional pharmacological active ingredient or a defined molecular target, operating instead under the principles of potentization and dilution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on strychnos nux-vomica.